I was just reading a similar understanding at the Rare Disease Report (RDR) article dated yesterday (Wed June 13, 2013). The article's title is Eteplirsen Treatment in Duchenne Muscular Dystrophy – Week 8. It has the remark
"As RDR reported last month, Sarepta has submitted two papers to the FDA (one on surrogate markers and one on clinical outcomes) and while Mr Garabedian downplayed his concerns with what the FDA will say about those papers, we at Rare Disease Report are very interesting (sic) in hearing what the FDA will decide (likely at their next meeting tentatively scheduled for the end of July)."
Looks like we'll be getting news on AA by the end of July.
"we expect that at that meeting, they'll have reviewed the two documents we submitted one on dystrophin, one on clinical outcomes to be able to make their recommendation or guidance for us on whether or not a accelerated approval NDA that we would submit will be accepted for filing"